


COVID-19 Tracker Canada	cipation Tracker		Menu 👻
vaccination, Ca	32,926,064 doses delivered 90.5% of doses delivered have been administered ® ehind other count nada is now amo ge of the populat	ong the leaders v	vhen it comes
https://covid19tracker.ca/	vaccinationtracker.html		




	Vaccine candidates						
	mRNA vaccines		Replication-defective v	ctored vaccines	Protein subunit		
	mRNA-1273 (Moderna)	mRNA-BNT162b2 (BloNTech/Pfizer)	AZD1222 (AstraZeneca) Vaxzevria	JNJ-78436735 (J&J)	NVX-CoV2373 (Novavax)		
Manufacturer	Moderna/NIAID	Pfizer Inc/BioNTech SE	AstraZeneca	Janssen	Novavax		
FDA status (if authorized, indication)	EUA – For active immunization to prevent COVID-19 caused by SARS- CoV-2 in individuals aged ≥ 18 y, Submission for EUA ≥ 12 y likely to occur in June.	EUA – For active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged ≥ 12 y	Investigational	EUA – For active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged ≥ 18 y	Investigational – EUA expected to be submitted in September		
Vaccine platform technology	LNP-encapsulated, nucleoside-modified mRNA vaccine	LNP formulated, nucleoside-modified mRNA vaccine	Recombinant, replication defective simian adenovirus vector	Recombinant, replication- defective adenovirus type 26 vector leveraging AdVac technology	Recombinant nanoparticle vaccine technology, leveraging Sf9/BV insect cell platform and Matrix- M™ adjuvant technology		
Pharmacology	 mRNA encoding for the SARS-CoV-2 spike glycoprotein is delivered to cells in a lipid capsule Using mRNA, cells manufacture the spike protein (antigen) Spike protein stimulates the body's immune response and production of antibodies against SARS-CoV-2 		(antigen) is encoded into adenovirus. Upon deliver manufacture the spike pr stimulates the body's imr uses a simian adenovirus human adenovirus with a Due to genetic alteration	to the host cell, host cells tein (antigen), which une response. AZD 1222 and JNJ-78436735 uses a low prevalence in humans. , adenovirus vectors are tion-defective) once in the	Genetic sequence encoding the antigen (spike protein) is cloned into baculovirus and inserted into Sr9 insect cells, where the antigen is produced and subsequently isolated/extracted. Matrix-M ad'uvant boosts immune response and enables vaccine dose- sparing by stimulating entry of antigen- presenting cells into the injection site and enhancing B- and T-cell ensponses.		


CDC, FDA to Resume J&J COVID-19 Vaccination Following Pause Over Rare Clots


Total of 15 cases of clots have been identified in J&J vaccine recipients, <u>all in women</u>. Nearly 10 potential cases are still under review. Among the data presented:


- The rate of clots estimated to be about 1.9 per million people vaccinated with the J&J vaccine
- Women aged 18 to 49 years, the clot rate is higher, at 7.0 per million. Women in their 30s had the highest rate
- Consideration from this vaccine:
 - Men
 - Women over the age of 50



	Vaccine candidates					
	mRNA vaccines		Replication-defective vector	red vaccines	Protein subunit	
	mRNA-1273 (Moderna)	mRNA-BNT162b2 (BioNTech/Pfizer)	AZD1222 (AstraZeneca)	JNJ-78436735 (J&J)	NVX-CoV2373 (Novavax)	
Symptomatic COVID-19 (with or without previous SARS- CoV-2 infection)	 Subgroup analysis, measured 14 d after dose 2 187 cases in placebo group vs. 12 cases in vaccine group VE: 93.6% (95% CI, 88.6-96.5) 	 Primary endpoint, measured 7 d after dose 2 169 cases in placebo group vs. 9 cases in the vaccine group VE: 94.6% (95% CI, 89.9-97.3) 	Not reported	 Secondary endpoint, measured 14 d and 28 d after vaccine 14 d: VE of 66.1% (95% CI, 59.7-71.6) 28 d: VE of 65.5% (57.2-72.4) 	Not reported	
Moderate or severe COVID-19	 Secondary endpoint, severe COVID-19 30 cases observed in placebo group vs. 0 cases in vaccine group (note: 1 vaccine recipient met definition for severe disease, but negative SARS-CoV-2 at hospital, but previously positive) VE: 100% (95% CI, not estimated) 	 Secondary endpoint, severe COVID-19 After dose 1: 9 cases in placebo group vs. 1 case in vaccine group After dose 2: 4 cases in placebo group vs. 1 case in vaccine group VE, after dose 2: 75% (95% CI, -152.6-99.5) 	 Secondary endpoint, severe or critical COVID-19 and hospitalization 8 cases observed in placebo group vs. 0 cases in vaccine group VE: 100% 	 Primary endpoint, moderate to severe/critical COVID- 19, measured 14 and 28 d after vaccine 14 d: 348 cases in placebo group vs. 116 cases in vaccine group; VE of 66.9% (95% CI, 59-73.4) 28 d: 193 cases in placebo group vs. 66 cases in vaccine group; VE of 66.1% (95% CI, 55-74.8) U.S. only: VE of 72% (95% CI, 58.2-81.7) 	 5 severe cases (including hospitalization/death) in placebo group vs. 0 cases in vaccine group (4 of 5 severe cases were caused by UK variant) VE: 100% 	








COVID-19 Vaccines: Real-World Effectiveness

In the United States, the real-world effectiveness of the COVID-19 mRNA vaccines is 90%, CDC researchers reported in *MMWR*

- 4K* from eight U.S. locations self-collected nasal swabs PCR testing each week, regardless of symptoms, between mid-December and mid-March. Those with prior evidence of SARS-CoV-2 infection were excluded.
- 63% received two doses of mRNA vaccine, and 12% received one dose, during the study period
- Incidence rate of infection was 1.38 per 1000 person-days in unvaccinated people, 0.19 per 1000 in partially vaccinated people (≥14 days after the first dose and before the second), and 0.04 per 1000 in fully vaccinated people (≥14 days after second dose)
- This translated to an effectiveness of 80% for partial vaccination and 90% for full vaccination.


*healthcare workers, first responders, and other essential or frontline workers





Pfizer: Vaccine Shown 100% Effective in Kids 12-15 in Phase III

- · 2,260 adolescents ages 12-15
- · No infections were reported in the group given the vaccine
- · Placebo group reported 18 cases of COVID-19
- The vaccinated children showed a strong antibody response with no serious side effects



Moderna Variant Trail

A version of Moderna's vaccine designed to protect against the B.1.351 variant has begun testing in a phase 1 trial sponsored by the National Institute of Allergy and Infectious Diseases

- The trial will enroll 210 volunteers, some of whom have previously received the original Moderna vaccine, and will test the candidate vaccine (known as mRNA-1273.351) alone or in various combinations with the original vaccine
- The trial's aim is to assess the candidate vaccine's safety, reactogenicity, and ability to induce an immune response


National Institutes of Health

15

<text><text><text><page-footer>

Heterologous Vaccination

- This is not a new concept. In the past, different vaccine products have been used to complete a vaccine series for influenza, hepatitis A, and others to complete a vaccine series for influenza, hepatitis A, and others.
- Basically, all vaccines work by showing people's immune systems something that looks like an invading virus but really isn't. If the real virus ever comes along, their immune systems will recognize it and be prepared to fight it off.
- Using two different vaccines is a bit like giving the immune system two pictures of the virus, maybe one face-on and one in profile.



Pfizer, Moderna COVID-19 vaccines effective in pregnant, lactating women

The Pfizer/BioNTech and Moderna [COVID-19] vaccines are effective in pregnant and lactating women, who can pass protective antibodies to newborns

- Study researchers looked at 131 women who received either the Pfizer/BioNTech or Moderna [COVID-19] vaccine
- Vaccine-induced antibody levels were equivalent in pregnant and lactating women, compared to non-pregnant women
- Antibody levels were strikingly higher than those resulting from coronavirus infection during pregnancy

the American Journal of Obstetrics and Gynecology

Safety of vaccine in pregnancy


Early results indicate that COVID-19 vaccination appears to be safe in the third trimester of pregnancy, according to a CDC study in the New England Journal of Medicine:

- Post-vaccine local and systemic events seem to be similar between pregnant and nonpregnant individuals
- Spontaneous abortion was 12.6% among vaccinated compared to 10% to 26%
- Completed pregnancy, the rates of adverse pregnancy and neonatal outcomes appear to be similar to prepandemic rates
- Among the pregnancies that ended in a live birth, 98% received their first vaccine dose in the third trimester

Facial paralysis

- The COVID-19 mRNA vaccines do not appear to pose any higher risk for facial paralysis than other viral vaccines, according to an analysis in JAMA Internal Medicine:
- 135K adverse drug reactions linked to the mRNA vaccines reported to the WHO's pharmacovigilance database, 0.6% were facial paralysis-related events (e.g., paralysis, paresis, spasms)
- The majority of these were linked to the Pfizer-BioNTech vaccine, and the median time to onset was 2 days
- For comparison, facial paralysis events accounted for 0.5% of adverse reactions to other viral vaccines and 0.7% of reactions to influenza vaccines

Autoimmune phenomenon or virus that affects nerves - VERY rare



FDA official says myocarditis is rare among adolescents, young adults who receive COVID-19 vaccines, connection to shot remains unclear


VaST concluded that there are relatively few reports of myocarditis to date and that these cases seem to occur:

- Predominantly in adolescents and young adults
- More often in males than females
- More often following dose 2 than dose 1
- Typically, within 4 days after vaccination

Most cases appear to be mild, and follow-up of cases is ongoing.

The Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Safety Technical (VaST) Work Group





Lessons from COVID-19 Vaccination Programs in Healthcare Workers

- Israel, weekly incidence of COVID-19 among vaccinated HCWs began to fall starting about 2 weeks after the first dose of the Pfizer vaccine then continued to decline and remained low after the second dose. This reduction occurred even as the B.1.1.7 variant became the dominant lineage in Israel
- University of Texas Southwestern between December 15, 2020, and January 28, 2021, infections occurred in 2.61% of nonvaccinated employees, 1.82% of partially vaccinated employees, and only 0.05% of fully vaccinated employees; the infection rate was >50-fold lower in the fully vaccinated group than in nonvaccinated HCW, coinciding with a >90% decrease in the number of HCWs in guarantine

25

Lessons from COVID-19 Vaccination Programs in Healthcare Workers

- 36,659 HCWs in California who received at least one dose of an mRNA vaccine, about 1% subsequently had a positive test; however, 71% of these infections were detected within 2 weeks of the first dose. Of 28,184 employees who received two doses, only 0.05% tested positive ≥8 days after the second vaccination
- Three weeks after receiving the first dose of BNT162b2, HCWs in Kansas with recent SARS-CoV-2 infection (or positive antibody responses at baseline) had higher levels of anti-SARS-CoV-2 antibodies than HCWs without any history of infection

Lessons from COVID-19 Vaccination Programs in Healthcare Workers

- 36,659 HCWs in California who received at least one dose of an mRNA vaccine, about 1% subsequently had a positive test; however, 71% of these infections were detected within 2 weeks of the first dose. Of 28,184 employees who received two doses, only 0.05% tested positive ≥8 days after the second vaccination
- Three weeks after receiving the first dose of BNT162b2, HCWs in Kansas with recent SARS-CoV-2 infection (or positive antibody responses at baseline) had higher levels of anti-SARS-CoV-2 antibodies than HCWs without any history of infection

27

Final Thoughts

- For the India variant (Delta) mRNA is still very protective 60-65% versus our 90+%
- The rising India variant, is increasing, roughly 10% of cases and more so in the southern states. Studies show it is more contagious, more severe symptoms and increased hospitalizations. For those who may not want to vaccine their children (for lack of data on long term effects)
- Vaccinated individuals cannot be carriers of the virus based on current data
- Complacency is NOT a solution and should NOT be an option
- Separate flu and COVID vaccines by 2 weeks